Physician profile
Jonathan Philip Sharp
NPI 1518768803
$1,173.20
in general payments reported to CMS, 2019-2025
9 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $395.29 | 2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $255.58 | 2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.27 | 2025 | Caplyta |
| Alkermes, INC. | $162.50 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Alpha Cognition USA, INC. | $76.56 | 2025 | Zunveyl |
| Vanda Pharmaceuticals INC. | $57.96 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $25.84 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $15.30 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $13.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.